Citadel Advisors’s BioCardia BCDA Stock Holding History

Citadel Advisors’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-67	Closed	-$664	–	14554
2023 Q4	$664	Sell	67 -246	-79%	-$2K	﹤0.01%	13972
2023 Q3	$2.01K	Sell	313 -780	-71%	-$13.1K	﹤0.01%	13773
2023 Q2	$43.8K	Sell	1,093 -2,287	-68%	-$70.5K	﹤0.01%	11964
2023 Q1	$99.4K	Buy	3,380 +1,573	+87%	+$52.2K	﹤0.01%	11270
2022 Q4	$56.6K	Buy	1,807 +114	+7%	+$3.24K	﹤0.01%	11971
2022 Q3	$49K	Buy	+1,693	New	+$43.8K	﹤0.01%	11642
2022 Q2	–	Sell	-2,573	Closed	-$80K	–	12870
2022 Q1	$80K	Sell	2,573 -67	-3%	-$1.99K	﹤0.01%	12477
2021 Q4	$77K	Buy	+2,640	New	+$96.8K	﹤0.01%	12970
2021 Q2	–	Sell	-2,360	Closed	-$154K	–	13659
2021 Q1	$154K	Buy	+2,360	New	+$147K	﹤0.01%	11995

Other funds holding BCDA

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pingora Partners Wilson, Wyoming $171M AUM 60.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Citadel Advisors's BCDA Position: Q2 2026 in Review

Citadel Advisors reduced its BioCardia (BCDA) stake by 64% in Q2 2026, selling an estimated $42.6K and leaving 22,956 shares worth $28.5K. The position accounts for ﹤0.01% of the portfolio, ranked #13316.

Citadel Advisors first reported a position in BCDA in Q4 2020 and has held it in 14 quarters since. The position peaked at $125K in Q2 2021. 21 funds tracked by Wall St. Rank hold BCDA as of Q2 2026.

Citadel Advisors held 22,956 shares of BioCardia worth $28.5K as of Q2 2026.
Citadel Advisors sold 40,428 BioCardia shares in Q2 2026, an estimated $42.6K.
BioCardia made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13316 holding.
Citadel Advisors first reported a position in BioCardia in Q4 2020 and has held it in 14 quarters since.
Citadel Advisors's BioCardia position peaked at $125K in Q2 2021.
21 funds tracked by Wall St. Rank held BioCardia as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.